Bryan Oronsky

Dr. Bryan Oronsky serves as EpicentRx Chief Development Officer and combines firsthand clinical experience as a physician with 17 years of pharmaceutical development experience. EpicentRx’s pipeline includes treatments that are intended to not only reverse resistance to standard therapies like chemotherapy and checkpoint inhibitors but also to improve their tolerability. The company’s small molecule, RRx-001 is one of the most advanced direct NLRP3 inflammasome inhibitors in clinical development and has been evaluated in over 300 multimorbid cancer patients both alone and in combination with other therapies. RRx-001 has been evaluated in multiple independent studies for conditions where immune and inflammasome activation contribute to disease pathology. These include cancer, myocardial infarction, pulmonary hypertension, acute kidney injury, acute radiation syndrome (ARS), malaria, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.

Posts by Bryan Oronsky